Search research articles
Contact Us
Filters
Showing results (101-110 of 249) with videos related to
Page
of 25
Sort By:
Leukemia Research
|
May 2, 2008
Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis
Laurent Jallades, Sandrine Hayette, Isabelle Tigaud, et al.
Cancer Medicine
|
December 17, 2016
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Francine Foss, Barbara Pro, H Miles Prince, et al.
The Lancet. Oncology
|
February 8, 2003
Splenic marginal-zone lymphoma: a distinct clinical and pathological entity
Catherine Thieblemont, Pascale Felman, Evelyne Callet-Bauchu, et al.
Clinical Drug Investigation
|
July 14, 2009
Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care
Ruth Pettengell, Matti Aapro, Ercole Brusamolino, et al.
Leukemia & Lymphoma
|
March 16, 2013
Pregnancy and multiple myeloma are not antinomic
Gabriel Brisou, Fadhela Bouafia-Sauvy, Lionel Karlin, et al.
European Cytokine Network
|
April 15, 2006
Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma
Ewa Lech-Maranda, Jacques Bienvenu, Anne-Sophie Michallet, et al.
Experimental Hematology & Oncology
|
May 5, 2015
Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis
Georg Hess, Bertrand Coiffier, Michael Crump, et al.
Leukemia & Lymphoma
|
December 30, 2009
Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study
Anna Johnston, Fadhela Bouafia-Sauvy, Florence Broussais-Guillaumot, et al.
Journal of Hematology & Oncology
|
March 12, 2016
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Francine Foss, Steven Horwitz, Barbara Pro, et al.
Journal of Hematology & Oncology
|
September 20, 2017
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Francine Foss, Steven Horwitz, Barbara Pro, et al.
Page
of 25
Search research articles
Search
Showing results (101-110 of 249) with videos related to
Sort By:
Page
of 25
Leukemia Research
|
May 2, 2008
Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis
Laurent Jallades, Sandrine Hayette, Isabelle Tigaud, et al.
Cancer Medicine
|
December 17, 2016
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Francine Foss, Barbara Pro, H Miles Prince, et al.
The Lancet. Oncology
|
February 8, 2003
Splenic marginal-zone lymphoma: a distinct clinical and pathological entity
Catherine Thieblemont, Pascale Felman, Evelyne Callet-Bauchu, et al.
Clinical Drug Investigation
|
July 14, 2009
Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care
Ruth Pettengell, Matti Aapro, Ercole Brusamolino, et al.
Leukemia & Lymphoma
|
March 16, 2013
Pregnancy and multiple myeloma are not antinomic
Gabriel Brisou, Fadhela Bouafia-Sauvy, Lionel Karlin, et al.
European Cytokine Network
|
April 15, 2006
Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma
Ewa Lech-Maranda, Jacques Bienvenu, Anne-Sophie Michallet, et al.
Experimental Hematology & Oncology
|
May 5, 2015
Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis
Georg Hess, Bertrand Coiffier, Michael Crump, et al.
Leukemia & Lymphoma
|
December 30, 2009
Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study
Anna Johnston, Fadhela Bouafia-Sauvy, Florence Broussais-Guillaumot, et al.
Journal of Hematology & Oncology
|
March 12, 2016
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Francine Foss, Steven Horwitz, Barbara Pro, et al.
Journal of Hematology & Oncology
|
September 20, 2017
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Francine Foss, Steven Horwitz, Barbara Pro, et al.
Page
of 25